March 2018


Options: Use Proportional Font
Show HTML Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
"Diane St. Germain" <[log in to unmask]>
Reply To:
Diane St. Germain
Thu, 8 Mar 2018 17:07:47 +0000
text/plain (2501 bytes) , text/html (9 kB)

Dissertation Defense Announcement
To:  The George Mason University Community

Candidate: Lindsay Lundberg

Program: PhD in Biosciences

Date:   Thursday March 22, 2018

Time:   10:00 AM
Place:  George Mason University
             Science & Tech Campus<>

             Institute for Advanced Biomedical Research, Room 1004

Title: "Venezuelan Equine Encephalitis Virus Capsid and Host Nucleocytoplasmic Trafficking"
Committee Chair: Dr. Kylene Kehn-Hall
Committee Members:  Dr. Aarthi Narayanan, Dr. Mikell Paige, Dr. Yuntao Wu

This is a public defense and all are invited to attend.
Venezuelan equine encephalitis virus (VEEV) is endemic to South, Central, and North America and causes an acute, febrile-like illness in humans that occasionally progresses to neurological involvement and rarely death. There are no FDA-approved therapeutics or vaccines for human use. It was weaponized by both the US and USSR and is considered a Category B Select Agent by the CDC. Thus, it is imperative to understand the interactions between host and viral proteins to develop targeted therapeutics that modulate host responses. VEEV capsid is known to directly interact with the host export protein, CRM1, and the import proteins, importin /1, forming a tetrameric complex that halts nucleocytoplasmic trafficking, downregulates host transcription, and alters the cell cycle. It is hypothesized that interfering with this interaction will reduce viral titers and pathogenesis and restore dysregulated cell functions by segregating capsid during viral assembly, freeing the nuclear pore to transport cellular factors that will help counter infection and promote cell survival. To that end, in silico and in vitro compound screens were performed to identify novel inhibitors of importin  and capsid, yielding new scaffolds for further research. The importin  inhibitor mifepristone was chemically modified, producing additional compounds to test for antiviral efficacy. Novel inhibitors of export, specifically CRM1, were also tested for antiviral efficacy but failed to protect mice in an infection model. Finally, the infection induced delay in G1 of the cell cycle was traced to VEEV capsid, and the cell cycle aberration was confirmed on both the protein and RNA levels. This body of work demonstrates multiple novel chemical scaffolds targeting VEEV capsid which have the potential for further antiviral drug development.